Cell Transplantation最新文献_第5页

Chimeric antigen receptor T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study. 嵌合抗原受体t细胞治疗难治性/复发性原发性乳腺淋巴瘤：一项回顾性队列研究。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-10-10 DOI: 10.1177/09636897261497148

Wanying Liu, Jiao Meng, Jiaying Wu, Xiaojian Zhu, Fankai Meng, Yang Cao, Zhen Shang, Mi Zhou, Liting Chen, Jinhuan Xu, Yi Xiao

{"title":"Chimeric antigen receptor T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study.","authors":"Wanying Liu, Jiao Meng, Jiaying Wu, Xiaojian Zhu, Fankai Meng, Yang Cao, Zhen Shang, Mi Zhou, Liting Chen, Jinhuan Xu, Yi Xiao","doi":"10.1177/09636897261497148","DOIUrl":"https://doi.org/10.1177/09636897261497148","url":null,"abstract":"Patients with relapsed or refractory primary breast lymphoma (r/r PBL) face a poor prognosis, and data regarding chimeric antigen receptor (CAR) T-cell therapy for this specific population remain scarce. This retrospective study aimed to evaluate the clinical efficacy and toxicity of CAR T-cell therapy (CD19 or sequential CD19/CD22), administered either alone or combined with autologous stem cell transplantation (ASCT), in 11 adult patients with r/r PBL. The cohort included nine patients with diffuse large B-cell lymphoma and two with Burkitt lymphoma. The treatment demonstrated high efficacy: at three months post-treatment, the overall response rate was 81.8%, and the complete remission rate was 72.7% (eight patients). Over a median follow-up of 38 months, seven patients remained alive, yielding estimated 1-year overall and progression-free survival rates of 63.6% and 61.4%, respectively. Notably, the safety profile was highly favorable; no patients experienced grade 3-4 cytokine release syndrome or any grade of immune effector cell-associated neurotoxicity syndrome. In conclusion, CAR T-cell therapy, with or without ASCT, represents a highly effective and safe therapeutic strategy for adult patients with r/r PBL, offering durable remissions with manageable toxicities.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261497148"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xenopax from a real-world and economic perspective: The future of second-line treatment and prophylaxis for SR-aGVHD. 从现实世界和经济角度看Xenopax: SR-aGVHD二线治疗和预防的未来。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-04-24 DOI: 10.1177/09636897251413325

Yigeng Cao, Erlie Jiang

{"title":"Xenopax from a real-world and economic perspective: The future of second-line treatment and prophylaxis for SR-aGVHD.","authors":"Yigeng Cao, Erlie Jiang","doi":"10.1177/09636897251413325","DOIUrl":"10.1177/09636897251413325","url":null,"abstract":"Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major therapeutic challenge after allogeneic hematopoietic stem cell transplantation. Although ruxolitinib and basiliximab are widely used, their limitations highlight the need for safer, more effective, and scalable biologic strategies. Xenopax, a humanized anti-CD25 monoclonal antibody, has demonstrated encouraging results across real-world and clinical studies. The multicenter RELAX study reported a 28-day overall response rate of 64.5% and a 2-year overall survival of 68.0%, with reduced corticosteroid exposure and infection rates compared with historical basiliximab cohorts. Importantly, RELAX incorporated an economic assessment, showing a lower incremental cost per responder and reinforcing xenopax as a cost-efficient option for SR-aGVHD. Beyond salvage therapy, xenopax is gaining momentum in prophylactic settings, including as a potential replacement for methotrexate in haploidentical transplantation. Looking ahead, integration with autonomous decision-support systems-most notably daGOAT, the first AI platform validated to prescribe risk-adapted GVHD prophylaxis-may further strengthen CD25-targeted approaches. Together, these developments position xenopax as a versatile biologic with the potential to reshape both treatment and prevention paradigms in GVHD management.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251413325"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic studies of hydrogels in oral cancer treatment: Synergistic effects of drug delivery and immune modulation. 水凝胶在口腔癌治疗中的机理研究：药物传递和免疫调节的协同作用。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-02-18 DOI: 10.1177/09636897261417200

Yilidanna Dilixiati, Huan-Huan He, Tianqi Wu, Wei An, Maimaitituxun Tuerdi

{"title":"Mechanistic studies of hydrogels in oral cancer treatment: Synergistic effects of drug delivery and immune modulation.","authors":"Yilidanna Dilixiati, Huan-Huan He, Tianqi Wu, Wei An, Maimaitituxun Tuerdi","doi":"10.1177/09636897261417200","DOIUrl":"10.1177/09636897261417200","url":null,"abstract":"Oral cancer ranks among the most prevalent malignant tumors of the head and neck, comprising 1%-2% of all global malignancies. Despite advancements in surgery, radiotherapy, chemotherapy, and immunotherapy, challenges remain in oral cancer treatment, including high recurrence rates, severe side effects, and limited efficacy. Hydrogels, biocompatible materials with a three-dimensional network structure, have emerged as promising candidates in oral cancer therapy due to their dual roles in drug delivery and immune modulation. This review examines the contribution of hydrogels to oral cancer treatment through their synergistic control of drug release and localized immune activation. By enabling targeted, stimuli-responsive drug release, and enhancing local immune responses, hydrogels reduce systemic toxicity and improve treatment precision. When integrated with advanced approaches such as gene therapy and immune modulation, hydrogels hold potential to further amplify therapeutic efficacy. Although preclinical results are promising, clinical translation requires addressing scalability, quality control, and long-term safety concerns. With ongoing development, hydrogels are positioned to become vital tools in the treatment of oral cancer, periodontitis, and other oral diseases.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261417200"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial transplantation as an immunomodulatory strategy: Modulating polymorphonuclear leukocytes for functional tissue regeneration. 线粒体移植作为一种免疫调节策略：调节多形核白细胞的功能组织再生。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-06-03 DOI: 10.1177/09636897261453307

Samantha C Hall, Evan N Main, Gary L Bowlin

{"title":"Mitochondrial transplantation as an immunomodulatory strategy: Modulating polymorphonuclear leukocytes for functional tissue regeneration.","authors":"Samantha C Hall, Evan N Main, Gary L Bowlin","doi":"10.1177/09636897261453307","DOIUrl":"10.1177/09636897261453307","url":null,"abstract":"Following biomaterial implantation, modulation of the acute immune response is essential for tissue regeneration. Polymorphonuclear leukocytes (PMNs) are critical effector cells in wound healing, and PMN dysfunction is mediated by mitochondrial dysfunction and can lead to prolonged inflammation and tissue damage. It was hypothesized that mitochondrial transplantation could be applied to PMNs in pro-inflammatory states as a means of upregulating regenerative proteins. Primary human PMNs were isolated from donor blood. Isolated PMNs and exogenous mitochondria were co-incubated to induce mitochondrial transplantation. Resulting interactions were assessed through microscopy to confirm initial uptake and mitochondria membrane potential retention, intracellular reactive oxygen species (ROS) analyses (n = 5), and PMN secretome quantification (n = 10) using multiplex protein analysis. Human PMNs were able to successfully uptake delivered mitochondria, and regenerative factors essential for tissue repair and immune cell recruitment including fibroblast growth factor-2 (FGF-2), interleukin (IL)-22, monocyte chemoattractant protein-1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) were significantly upregulated, indicating that exogenous mitochondria represent promising modulators of PMN function with broad clinical potential.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261453307"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addition of human platelet lysate to islet culture medium suppresses islet loss and improves transplantation outcomes. 在胰岛培养液中加入人血小板裂解液可抑制胰岛损失并改善移植结果。

IF 3.2 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-01-03 DOI: 10.1177/09636897251410290

Hirofumi Noguchi, Chika Miyagi-Shiohira, Takuya Sadahira, Masami Watanabe, Issei Saitoh

引用次数: 0

Corrigendum to "Standardized dynamic glucose testing reveals donor-dependent heterogeneity in human islet function". “标准化动态葡萄糖测试揭示了人类胰岛功能的供体依赖性异质性”的勘误。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-01-09 DOI: 10.1177/09636897251400521

引用次数: 0

Management of donor-specific antibodies in allogeneic hematopoietic cell transplantation: A retrospective single-center case-control study. 同种异体造血细胞移植中供体特异性抗体的管理：一项回顾性单中心病例对照研究。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-09-09 DOI: 10.1177/09636897261486247

Lennart Harland, Semian L Schüch, Sarah Katzenstein, Sandra Hammer, Christoph Faul, Karina Althaus, Bernhard N Bohnert, Markus W Löffler, Tamam Bakchoul, Claudia Lengerke, Wolfgang A Bethge

{"title":"Management of donor-specific antibodies in allogeneic hematopoietic cell transplantation: A retrospective single-center case-control study.","authors":"Lennart Harland, Semian L Schüch, Sarah Katzenstein, Sandra Hammer, Christoph Faul, Karina Althaus, Bernhard N Bohnert, Markus W Löffler, Tamam Bakchoul, Claudia Lengerke, Wolfgang A Bethge","doi":"10.1177/09636897261486247","DOIUrl":"10.1177/09636897261486247","url":null,"abstract":"Donor-specific antibodies (DSA) are preformed recipient antibodies directed against donor HLA antigens, most frequently observed in haploidentical or mismatched allogeneic hematopoietic cell transplantation (HCT). DSA assessed by multiplexed bead-based immunoassays at mean fluorescence intensity (MFI) values >1 000 are associated with increased risk of graft failure, graft-versus-host disease (GvHD), and mortality, supporting combined pharmacological and plasma-based depletion in absence of matching donors. We retrospectively analyzed all adult HCTs performed between 2009 and 2025 at the University Hospital Tübingen, Germany, with clinically relevant DSA (MFI >1 000). Assessments included depletion strategies, engraftment, GvHD, overall survival, and immune reconstitution. A 2:1 matched control cohort without DSA was selected based on disease, age, sex, and donor features. Fourteen cases were identified (1.2% of all transplants; 9.1% of haploidentical procedures). Depletion regimens included rituximab (n=12), bortezomib (n=10), daratumumab (n=2), intravenous immunoglobulins (n=6), plasma exchange (n=8), and immunoadsorption (n=9). MFI reduction <1 000 before HCT was achieved in 5 of 11 evaluable patients. All but two recipients engrafted timely; both graft failures occurred after single-modality depletion. Clinical outcomes did not differ significantly between DSA patients and controls. These real-world data underscore the importance of systematic DSA screening and multimodal depletion to optimize transplantation outcomes.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261486247"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering chromatin loops to control cell fate: LoopID reveals catalytic-independent functions of epigenetic regulators. 工程染色质环控制细胞命运：LoopID揭示了表观遗传调控因子的催化独立功能。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-02-17 DOI: 10.1177/09636897261424577

Huanhuan Li, José C R Silva

{"title":"Engineering chromatin loops to control cell fate: LoopID reveals catalytic-independent functions of epigenetic regulators.","authors":"Huanhuan Li, José C R Silva","doi":"10.1177/09636897261424577","DOIUrl":"10.1177/09636897261424577","url":null,"abstract":"Enhancer-promoter (E-P) interactions are central to cell-type-specific transcriptional programs, yet the molecular machinery that establishes and maintains these loops has remained poorly defined. A recent study by Jiang et al, published in Nature Genetics, presents a series of transformative discoveries that redefine our understanding of E-P interactions and their role in gene regulation and cell fate determination. The research introduces LoopID, a chromatin-interaction-based proteomic platform that, for the first time, enables systematic identification of protein components, termed the \"looposome,\" localized specifically at chromatin looping anchors. Using LoopID, they profile the \"looposome\" in mouse embryonic stem cells (ESCs) and uncover an unexpected, catalytic-independent role for the histone demethylase JMJD2 (KDM4) in organizing chromatin architecture through phase-separated condensates. Beyond mechanism, the study demonstrates that targeted assembly of JMJD2 condensates at defined genomic loci can engineer E-P interactions driving cellular reprogramming toward pluripotent and two-cell-like states. Together, these findings represent not only a major technical advance but also a conceptual leap-establish LoopID as a foundational technology for dissecting chromatin structure, introduce a new conceptual framework for epigenetic regulators as structural organizers, and provide a powerful strategy to manipulate cell fate by rewiring three-dimensional (3D) genome architecture.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261424577"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human islet isolation optimization: Insights from donor and isolation procedural factors. 人胰岛分离优化：来自供体和分离程序因素的见解。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-03-24 DOI: 10.1177/09636897261433325

Qin Yang, Yinsheng Xi, Zhihong Yang, Hongping Deng, Zhenjuan Wang, Guoping Li, Kerry Augusta, Shimul Shah, James F Markmann, Ji Lei

{"title":"Human islet isolation optimization: Insights from donor and isolation procedural factors.","authors":"Qin Yang, Yinsheng Xi, Zhihong Yang, Hongping Deng, Zhenjuan Wang, Guoping Li, Kerry Augusta, Shimul Shah, James F Markmann, Ji Lei","doi":"10.1177/09636897261433325","DOIUrl":"10.1177/09636897261433325","url":null,"abstract":"This study investigated donor and islet isolation procedural factors influencing the islet yield during human islet isolation for transplantation. We retrospectively analyzed 133 islet isolations from deceased donors performed over 15 years at a single center. Isolations were stratified by post-purification islet yield (≥400,000 islet equivalents [IEQ], successful; <400,000 IEQ, unsuccessful) and by intent (clinical vs research). Higher donor body mass index and height over 170 cm were independently associated with successful isolation, whereas an enzyme perfusion temperature exceeding 14°C for ≥50% of the perfusion duration emerged as an independent risk factor for isolation failure. Clinically intended isolations exhibited tighter thermal control during Phase 1 digestion, greater digestion efficiency, and lower undigested tissue weight. A logistic regression model incorporating body surface area, packed tissue volume, and phase 1 digestion time (the interval from the start of warm recirculation to the collection phase) showed a moderate predictive value for isolation success (area under the curve = 0.755). Subgroup analysis revealed that longer relative phase 2 digestion time (the interval from the start of collection to its end) and higher North American Islet Donor Scores were associated with higher islet yield. These findings highlight the importance of donor anthropometrics, procedural consistency, and thermal regulation during islet isolation. Optimizing donor selection and controlling intra-procedural variables can improve islet yield and increase the likelihood of achieving the required clinical transplantation islet dose.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261433325"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13018692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound-guided intrarenal arterial injection promotes homing of MSCs and recovery of kidney in Adriamycin-induced nephropathy in rats. 超声引导肾动脉注射促进阿霉素肾病大鼠间充质干细胞归巢和肾脏恢复。

IF 3.7 4区医学

Cell Transplantation Pub Date : 2026-01-01 Epub Date: 2026-04-09 DOI: 10.1177/09636897261436945

Chunjuan Xia, Jiaping Wang, Xue Hu, Bosheng Luo, Yanpeng Kong

{"title":"Ultrasound-guided intrarenal arterial injection promotes homing of MSCs and recovery of kidney in Adriamycin-induced nephropathy in rats.","authors":"Chunjuan Xia, Jiaping Wang, Xue Hu, Bosheng Luo, Yanpeng Kong","doi":"10.1177/09636897261436945","DOIUrl":"10.1177/09636897261436945","url":null,"abstract":"To identify the optimal transplantation route for enhancing homing of mesenchymal stem cells (MSCs) to the kidney, thereby ameliorating rat Adriamycin nephropathy (AN). In vivo animal imaging revealed that ultrasound-guided intrarenal-arterial transplantation of GFP-MSCs markedly increased the number of MSCs homing to the kidney compared with the intravenous injection (IV) and renal parenchyma (RP) routes. Multimodal ultrasonography revealed that the renal artery (RA) group exhibited reduced renal parenchymal echogenicity and significantly increased cortical microvascular perfusion compared to the Adriamycin (ADR), IV, and RP groups. Hematoxylin and eosin (H&E) staining, Masson staining, and electron microscopy revealed that the RA group had an enlarged glomerular volume, diminished renal interstitial fibrosis, and attenuated mitochondrial damage compared to the ADR, IV, and RP groups. Western blotting, qRT-PCR and immunohistochemistry further indicated that the RA group mitigated rat AN by downregulating the JAK2, AKT1, and STAT3 signaling pathways more effectively than the ADR, IV, and RP groups did. The above findings indicate that under ultrasound guidance, MSCs transplanted via the renal artery can ameliorate AN-induced renal injury by acting on the JAK/STAT signaling pathway.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261436945"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0